Benefits vs risks of new antiepileptic drugs;Riesgos y beneficios de los nuevos antiepilêpticos en niños

Revista de Neurologia

Volumn 31, Issue 4, 2000, Pages 376-381

  Aicardi, J ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Antiepileptic drugs; Epilepsy syndromes; Monotherapy; Polytherapy

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; EPILEPSY; HUMAN; PRESCHOOL CHILD; RISK;

ANTICONVULSANTS; CHILD, PRESCHOOL; EPILEPSY; HUMANS; RISK;

EID: 0034674859     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3104.2000302     Document Type: Article

References (8)

1. Aicardi J. Epilepsy in Children. 2 ed. New York: Raven Press; 1994.
2. Pellock JM. Drug treatment in children. In Engel J Jr, Pedley T, eds. Epilepsy: A comprehensive Textbook. Vol. 2. Philadelphia: Lippincott-Raven; 1998. p. 1205-10.
3. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 39: 671-4.
4. Perucca E. The new generation of antiepileptic drugs. Advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43.
5. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 (Suppl 6): S4-11.
6. Pellock M, Brodie MJ. Felbamate: 1997 update. Epilepsia 1997; 38: 1261-2.
7. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, et al. Visual dysfunction in patients receiving vigabatrin. Clinical and electrophysiologic findings. Neurology 1999; 53: 2082-7.
8. Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood J Pediatr 1995; 127: 991-7.